Insurers Call For Greater Transparency In Compendia Process
Executive Summary
Third-party payers are looking for greater transparency in the processes that are used to generate compendia that list off-label uses of pharmaceuticals
You may also be interested in...
Clinical, Not Real-World, Data is Still The Key To On- And Off-Label Reimbursement (Part 2)
While payers have ever-more sophisticated datasets for observing drug use in the clinic, such information generally is “inconclusive” for reimbursement decisions, a managed care executive cautions.
Compendia Conflict Of Interest White Paper A Precursor To New Regulations
Compendia publishers can expect to see new regulations regarding transparency and conflict of interest by the end of the year, and those rules could have an effect on whether a compendium will be recognized by CMS as a source for making coverage decisions for off-label drug uses
Compendia Conflict Of Interest White Paper A Precursor To New Regulations
Compendia publishers can expect to see new regulations regarding transparency and conflict of interest by the end of the year, and those rules could have an effect on whether a compendium will be recognized by CMS as a source for making coverage decisions for off-label drug uses